CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment
- 12 April 2005
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 64 (7) , 1294-1297
- https://doi.org/10.1212/01.wnl.0000156914.16988.56
Abstract
Baseline CSF amyloid β-peptide-42 (Aβ42), tau, and phosphorylated tau (P-tau) levels from 46 control subjects and 78 patients with mild cognitive impairment (MCI) were measured. Twenty-three patients with MCI developed dementia during the study. Abnormal biomarkers were found early in the course of Alzheimer disease (AD). The most predictive assay for AD among the patients with MCI was the combination of Aβ42 and P-tau.Keywords
This publication has 8 references indexed in Scilit:
- Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's diseaseNeuroscience Letters, 2003
- Cerebrospinal Fluid Tau and β-Amyloid 42 Proteins Identify Alzheimer Disease in Subjects With Mild Cognitive ImpairmentArchives of Neurology, 2002
- Current Concepts in Mild Cognitive ImpairmentArchives of Neurology, 2001
- Tau and Aβ42 in Cerebrospinal Fluid from Healthy Adults 21–93 Years of Age: Establishment of Reference ValuesClinical Chemistry, 2001
- Mild Cognitive Impairment Represents Early-Stage Alzheimer DiseaseArchives of Neurology, 2001
- Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical PracticeArchives of Neurology, 2001
- Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSFNeurology, 1999
- High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E GenotypeArchives of Neurology, 1998